Screener / SEC EDGAR /CIK 0002046386 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

Medline Inc. MDLN

Compare with peers Embed
New in the 10-K - fewer than two 10-Ks to compare New in the 10-Q 22 paragraphs not in the 10-Q filed Aug 5, 2026 10-Q against the 10-K 0 risk factor paragraphs and sentences added or reworded

Paragraphs with nothing like them in last year's 10-K

Fewer than two 10-Ks to compare.

Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before

New in the latest 10-Q

22 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

10-Q

• We may not realize the expected benefits from planned cost savings and business improvement initiatives.

Read in the 10-Q

• Our insurance program may not cover claims brought against us, deny coverage of claims, or be inadequate to cover future losses.

Read in the 10-Q

Financial statements and notes

On October 22, 2026, the Company prepaid $ 750 million in aggregate principal amount of the 2033 Refinancing Term Loan Facility. See Note 17 - Subsequent Events for additional information.

Read in the 10-Q

In October 2026, the Company’s Board of Directors authorized a share repurchase program under which the Company may repurchase up to $ 1 billion of its outstanding Class A common stock and/or units of Medline Holdings (the “Share Repurchase Program”). Under the Share Repurchase Program, the Company is authorized to repurchase shares of Class A common stock and/or units of Medline Holdings through open market transactions (including pursuant to a plan intended to comply with the requirements of Rule 10b5-1 and/or Rule 10b-18 promulgated under the Exchange Act), block trades, tender offers, accelerated share repurchase programs, privately negotiated transactions or otherwise, or any combination of the foregoing in accordance with applicable securities laws and other restrictions. The Share Repurchase Program does not have an expiration date, does not obligate the Company to acquire any particular amount of Class A common stock and/or units of Medline Holdings, and may be suspended or terminated at any time at the Company's discretion.

Read in the 10-Q

In October 2026, the Company’s Board of Directors approved the prepayment of $ 750 million in aggregate principal amount of the 2033 Refinancing Term Loan Facility using cash on hand. Accordingly, this prepayment, together with the payment of accrued interest, was made on October 22, 2026. In connection with the prepayment, the Company recognized a loss on extinguishment of debt of approximately $ 21 million in the fourth quarter of 2026.

Read in the 10-Q
Show the other 17

In October 2026, the Company communicated to customers a voluntary field action related to a discontinuation and market exit of Medline Brand beds, including homecare beds, bariatric beds, and long-term-care beds, and associated rails, mattresses, and accessories. These communications established the Company’s commitment to provide customers with repair, replacement or refund for applicable products. The Company currently estimates the related costs to be approximately $ 50 million to $ 200 million, which are expected to be incurred in the fourth quarter of 2026 and 2027 and to be excluded from Adjusted EBITDA. The estimated range reflects uncertainty regarding future customer participation, and actual costs and customer credits may differ materially.

Read in the 10-Q

Additionally, on September 16, 2026, we initiated a discontinuation and market exit of Medline Brand beds, including homecare beds, bariatric beds, and long-term care beds, and associated rails, mattresses, and accessories. On October 14, 2026, we communicated to customers a related voluntary field action advising customers that certain Medline Brand beds and associated products may be eligible for full or partial refund. On October 24, 2026, in consultation with the FDA, we issued an updated customer notification advising customers that certain Medline Brand beds and associated products may also be eligible for repair or replacement. Net sales of the affected products for the twelve months ended September 26, 2026, were approximately $50 million. In connection with the voluntary field action, we will provide customers with a replacement or credits for recalled products and facilitating repair for certain other impacted customers. For the three months ended September 26, 2026, we also recorded $13 million of inventory write-downs related to the market exit of the Medline Brand beds after initial communication to the FDA of plans to exit in September. We currently estimate the incremental related costs, including inventory write-downs, to be approximately $60 million to $210 million, which are expected to be incurred in the fourth quarter of 2026 and 2027 and to be excluded from Adjusted EBITDA. The estimated range reflects uncertainty regarding future customer participation, and actual costs and customer credits may differ materially.

Read in the 10-Q

In October 2026, management approved a restructuring plan intended to further align its organizational structure and cost base with its long-term strategic and operational objectives. Implementation of these initiatives is expected to occur over multiple reporting periods and may result in additional restructuring and related charges. We expect to incur approximately $20 million to $30 million in restructuring costs to be accrued in the fourth quarter of 2026 and excluded from Adjusted EBITDA. We expect the restructuring actions to generate approximately $80 million to $90 million of annualized run-rate cost savings upon full implementation.

Read in the 10-Q

(1) Represents the non-cash impact of last-in, first-out reserve changes attributable to changes in inventory costs.

Read in the 10-Q

a.Costs related to specified transformation and implementation projects of $11 million and $34 million, respectively.

Read in the 10-Q

b.Loss on debt extinguishment and other debt refinancing costs and fees related to specified financing transactions of $1 million and $46 million, respectively.

Read in the 10-Q

c.The impact attributable to a fire at the distribution center in Tracy, California, net of insurance proceeds of $(20) million and $316 million, respectively.

Read in the 10-Q

d.Costs attributable to specified remediation activities undertaken in response to the FDA observations and warning letters described above under “FDA and Quality Matters” of $13 million.

Read in the 10-Q

e.Recall and discontinuation costs related to Medline Brand beds of $13 million, as described above under “FDA and Quality Matters”.

Read in the 10-Q

f.Costs related to specified transformation and implementation projects of $3 million and $15 million, respectively.

Read in the 10-Q

g.Loss on debt extinguishment and other debt refinancing costs and fees related to specified financing transactions of $6 million.

Read in the 10-Q

h.Foreign exchange losses directly attributable to the remeasurement of euro-denominated term loans of $9 million and $84 million, respectively.

Read in the 10-Q

The nine months ended September 27, 2025 also includes $32 million credit loss expense related to certain customer receivable.

Read in the 10-Q

In October 2026, our Board of Directors authorized a share repurchase program under which we may repurchase up to $1 billion of our outstanding Class A common stock and/or units of Medline Holdings (the “Share Repurchase Program”). We may repurchase shares of Class A common stock and/or units of Medline Holdings from time to time through open market purchases, in privately negotiated transactions, or by other means in accordance with applicable securities laws and other restrictions. In determining the amount of capital to allocate to any future share repurchases, we will take into account, among other things, our historical and expected business performance and cash and liquidity position, as well as global economic and market conditions and the market price of our Class A common stock. The timing, manner, price and amount of any repurchases under the Share Repurchase Program will be determined by us in our discretion. The Share Repurchase Program does not have an expiration date, does not obligate us to acquire any particular amount of Class A common stock and/or units of Medline Holdings, and may be suspended or terminated at any time at our discretion. As of the date of this Quarterly Report, we had not repurchased any shares under the Share Repurchase Program.

Read in the 10-Q

On October 22, 2026, we prepaid $750 million in aggregate principal amount of our 2033 Refinancing Term Loan Facility under our Credit Agreement using cash on hand.

Read in the 10-Q

As of September 26, 2026, we had recorded a tax receivable agreement liability of $4,415 million. Assuming:

Read in the 10-Q

(i) a price of $34.70 per share of our Class A common stock, which was the closing sales price of our Class A common stock on September 25, 2026 as reported on Nasdaq;

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 25, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:There have been no material changes for the period covered by this Quarterly Report to the risk factors disclosed in Part I, “Item 1A - Risk Factors” of our 2025 Form 10-K.

Read in the 10-Q

1 paragraph in the 10-Q's Item 1A, and none of them adds, rewords or quietly edits a paragraph of the 10-K's.

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDLN/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.